Sign inJoin waitlistJoin the waitlist

Madeleine O’Keefe

Assistant Professor of Pediatrics · Mayo Clinic College of Medicine and Science

Credentials: · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Pediatric Hematology-Oncology
2020–2021
Pediatrics
Medical College of Wisconsin Affiliated Hospitals, Inc
2017–2020
Medical College of Wisconsin
2013–2017

Research

Murine Models of Acute Myeloid Leukemia
Review · Frontiers in Oncology · 2022 · 21 citations
Attempted desensitization to calaspargase pegol: a familiar approach to a new problem
Leukemia & lymphoma/Leukemia and lymphoma · 2024 · 2 citations
Standardizing the evaluation and management of iron deficiency anemia secondary to heavy menstrual bleeding in the emergency department
Pediatric Blood & Cancer · 2024 · 1 citations

Mira Kohorst
3 papers
Paul Galardy
3 papers
Jacob Greenmyer
2 papers · 2 as a fellow
Anand Srinivasan
1 paper
AF
Asmaa Ferdjallah
1 paper
Cecile Karsenty
1 paper
Chelsea Vrana
1 paper
CT
Christineil Thompson
1 paper
Clay Cohen
1 paper · 1 as a fellow
Gladstone Airewele
1 paper
Jacquelyn Powers
1 paper
Josaura Fernandez
1 paper · 1 as a fellow

Clinical trials

Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
Principal investigator · Not yet recruiting
Mayo Clinic
2027–2028
Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study
Principal investigator · Recruiting
Mayo Clinic
2025–2026
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Site PI · Recruiting · Phase 3
Children's Oncology Group
2019–2032